Arca Biopharma, Inc. (ABIO): Christopher David Ozeroff , S.V.P., General Counsel of Arca Biopharma, Inc. sold 1,185 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 21, 2016 to the Securities and Exchange Commission. The shares were sold at $2.89 per share for a total value of $3,424.65 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 21, 2016, Brian L. Selby (VP, Finance) sold 476 shares at $2.91 per share price.On Apr 6, 2016, Michael R Bristow (director officer ) sold 724 shares at $3.52 per share price.Also, On Apr 6, 2016, Thomas A Keuer (Chief Operating Officer) sold 384 shares at $3.52 per share price.On Apr 6, 2016, Christopher David Ozeroff (S.V.P., General Counsel) sold 366 shares at $3.52 per share price.
Shares of Arca Biopharma Inc (ABIO) ended Tuesday, Sep 21, 2016 session in red amid volatile trading. The shares closed down -0.04 points or -1.36% at $2.91 with 20,588 shares getting traded. Post opening the session at $2.9258, the shares hit an intraday low of $2.88 and an intraday high of $2.988 and the price vacillated in this range throughout the day. The company has a market cap of $26 M and the number of outstanding shares has been calculated to be 90,66,348 shares. The 52-week high of Arca Biopharma Inc is $6.97 and the 52-week low is $2.73.
ARCA biopharma Inc. (ARCA) is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride) a beta-blocker and mild vasodilator. Gencaro is being evaluated in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure and left ventricular systolic dysfunction (HFREF). Gencaro is part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2 receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules primarily the neurotransmitter norepinephrine (NE) which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro known as GENETIC-AF. Data from the Phase III HF trial of Gencaro in 2708 heart failure (HF) patients or the BEST trial suggested that Gencaro reduces or prevents AF.